Item 2.02. Results of Operations and Financial Condition.

On January 9, 2023, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year ended December 31, 2022 and providing new guidance for full year 2023 ORLADEYO net revenue and expected peak ORLADEYO sales. The press release also referenced a previously announced, upcoming webcast presentation by the Company at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2023 at 6:00 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

On January 9, 2023, the Company also issued a press release announcing initial data from ongoing phase 1 single ascending dose and multiple ascending dose trials in healthy volunteers. These data support the development of BCX10013 as a potential best-in-class, once-daily, oral Factor D inhibitor for multiple complement-mediated diseases. A copy of the press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.       Description

                    Press release dated January 9, 2023 entitled "BioCryst
  99.1            Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat)
                  Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue
                  Guidance"
                    Press release dated January 9, 2023 entitled "BioCryst Reports
  99.2            Initial Clinical Data with Oral Factor D Inhibitor BCX10013
                  Supporting Development as a Once-daily Treatment for
                  Complement-mediated Diseases"
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

© Edgar Online, source Glimpses